{"created":"2023-05-15T14:58:48.271065+00:00","id":79772,"links":{},"metadata":{"_buckets":{"deposit":"b503d6e7-dcc4-4c2b-971c-90fdf4949147"},"_deposit":{"created_by":1,"id":"79772","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"79772"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00079772","sets":["10:28"]},"author_link":["862245","862252","862256","862249","862255","862240","862241","862246","862247","862257","862254","862242","862250","862238","862253","862258","862243","862248","862237","862244","862239","862251"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2020-02-02","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background and Aims: Our previous studies demonstrated that 18F-PM-PBB3 (18F-APN-1607) uptake may reflect characteristic distributions of tau pathologies in 4-repeat tauopathies including progressive supranuclear palsy (PSP). The present study aimed to investigate the association among 18F-PM-PBB3 uptake, neurodegenerative biomarker level, and clinical symptoms in PSP with Richardson syndrome (PSP-RS) patients.\nMethods: 21 patients with probable PSP-RS underwent PET scans with 18F-PM-PBB3 and 11C-PiB for estimating regional tau and Aβ deposition. Plasma neurofilament light chain (NfL) levels were also checked as a neurodegenerative biomarker. Parametric 18F-PM-PBB3- and 11C-PiB- images were generated by voxel-based calculation of the standardized uptake value ratio (SUVR) to the cerebellar cortex. Three patients, who were diagnosed as amyloid-positive by visual assessment of 11C-PiB SUVR image, and two patients lacking some data (PET or NfL) were excluded. Finally, the other 18PiB-negative PSP-RS patients were included for further analyses. Regional 18F-PM-PBB3 SUVR was estimated in dentate, midbrain, subthalamus, striatum, pre- and post-central gyri in addition to PSP tau PET meta-ROI. We assessed Pearson’s correlation of regional 18F-PM-PBB3 SUVR with plasma NfL levels and motor severity assessed by PSP rating scale.\nResults: Plasma NfL levels showed positive correlation with 18F-PM-PBB3 SUVR in striatum, pre- and post-central gyri as well as PSP tau PET meta-ROI (r = 0.77, 0.98, 0.95, and 0.78; p < 0.05, followed by Bonferroni correction), and a trend toward significance in midbrain and dentate (r = 0.68 and 0.51; p = 0.008 and 0.043, without multiple comparison). PSP rating scale score positively correlated with plasma NFL (r = 0.73; p < 0.01, followed by Bonferroni correction), and there were trends towards significance between PSP rating scale and 18F-PM-PBB3 SUVR in midbrain and PSP tau PET meta-ROI (r = 0.66 and 0.65; p = 0.01 and 0.03, without multiple comparison).\nConclusions: Accumulations of PM-PBB3 may reflect neurotoxic tau pathologies in PSP-RS, in tight association with clinical symptoms.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"Takeda Expert Conference on Parkinson's Disease 2020","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Shimada, Hitoshi"}],"nameIdentifiers":[{"nameIdentifier":"862237","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Matsuoka, Kiwamu"}],"nameIdentifiers":[{"nameIdentifier":"862238","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kubota, Manabu"}],"nameIdentifiers":[{"nameIdentifier":"862239","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Takahata, Keisuke"}],"nameIdentifiers":[{"nameIdentifier":"862240","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Takado, Yuhei"}],"nameIdentifiers":[{"nameIdentifier":"862241","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Seki, Chie"}],"nameIdentifiers":[{"nameIdentifier":"862242","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ono, Maiko"}],"nameIdentifiers":[{"nameIdentifier":"862243","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sahara, Naruhiko"}],"nameIdentifiers":[{"nameIdentifier":"862244","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kawamura, Kazunori"}],"nameIdentifiers":[{"nameIdentifier":"862245","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ming-Rong, Zhang"}],"nameIdentifiers":[{"nameIdentifier":"862246","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Higuchi, Makoto"}],"nameIdentifiers":[{"nameIdentifier":"862247","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Shimada, Hitoshi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"862248","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Matsuoka, Kiwamu","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"862249","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kubota, Manabu","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"862250","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Takahata, Keisuke","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"862251","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Takado, Yuhei","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"862252","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Seki, Chie","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"862253","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ono, Maiko","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"862254","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sahara, Naruhiko","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"862255","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kawamura, Kazunori","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"862256","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ming-Rong, Zhang","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"862257","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Higuchi, Makoto","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"862258","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"18F-PM-PBB3 (18F-APN-1607) uptake associates with plasma NfL level and motor disability in patients with progressive supranuclear palsy","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"18F-PM-PBB3 (18F-APN-1607) uptake associates with plasma NfL level and motor disability in patients with progressive supranuclear palsy"}]},"item_type_id":"10005","owner":"1","path":["28"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-04-01"},"publish_date":"2020-04-01","publish_status":"0","recid":"79772","relation_version_is_last":true,"title":["18F-PM-PBB3 (18F-APN-1607) uptake associates with plasma NfL level and motor disability in patients with progressive supranuclear palsy"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T22:05:14.070710+00:00"}